Abstract
Oral chloroquine is the treatment of choice for uncomplicated Plasmodium malariae infections worldwide. We did a prospective 28-day in-vivo assessment of the efficacy of chloroquine for treatment of P malariae on Legundi Island in Lampung Bay, Sumatra, Indonesia. Of 28 patients, one had recurrent parasitaemia on day 28, and two had persistent parasitaemia to day 8. Whole-blood chloroquine and desethylchloroquine concentrations were at ordinarily effective levels (> or = 100 microg/L) on day 8 in both cases of persistent parasitaemia. These findings suggest that clinical resistance to chloroquine by P malariae occurs in the Indonesian archipelago of southeast Asia.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Animals
-
Antimalarials / blood
-
Antimalarials / therapeutic use*
-
Child
-
Chloroquine / blood
-
Chloroquine / therapeutic use*
-
Drug Resistance
-
Female
-
Humans
-
Indonesia / epidemiology
-
Malaria, Falciparum / blood
-
Malaria, Falciparum / drug therapy*
-
Malaria, Falciparum / epidemiology
-
Malaria, Vivax / blood
-
Malaria, Vivax / drug therapy*
-
Malaria, Vivax / epidemiology
-
Male
-
Middle Aged
-
Plasmodium falciparum / isolation & purification*
-
Plasmodium vivax / isolation & purification*
-
Polymerase Chain Reaction
-
Prevalence
-
Prospective Studies
Substances
-
Antimalarials
-
Chloroquine